{'52WeekChange': -0.9753732,
 'SandP52WeekChange': None,
 'address1': '5 Great Valley Parkway',
 'address2': 'Suite 160',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 0.3591,
 'askSize': 4000,
 'averageDailyVolume10Day': 58085900,
 'averageVolume': 17842679,
 'averageVolume10days': 58085900,
 'beta': None,
 'beta3Year': None,
 'bid': 0.346,
 'bidSize': 900,
 'bookValue': None,
 'category': None,
 'circulatingSupply': None,
 'city': 'Malvern',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 0.4083,
 'dayLow': 0.28,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -2.033,
 'enterpriseToRevenue': None,
 'enterpriseValue': 26805222,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 0.24885714,
 'fiftyTwoWeekHigh': 17.399965,
 'fiftyTwoWeekLow': 0.17,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 60919991,
 'forwardEps': None,
 'forwardPE': None,
 'fromCurrency': None,
 'fullTimeEmployees': 16,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.081520006,
 'heldPercentInstitutions': 0.119770005,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': 1569801600,
 'lastSplitFactor': '1:60',
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/ocugen.com',
 'longBusinessSummary': 'Ocugen, Inc., a clinical stage biopharmaceutical '
                        'company, focuses on discovering, developing, and '
                        'commercializing a pipeline of innovative therapies '
                        'that address rare and underserved eye diseases. The '
                        'company offers an ophthalmology portfolio that '
                        'includes novel gene therapies, biologics, and small '
                        'molecules, as well as targets a range of retinal and '
                        'ocular surface diseases. Its pipeline includes OCU400 '
                        'and OCU410 for the treatment of inherited retinal '
                        'disorders; OCU200 for the treatment of wet-AMD, DME, '
                        'and diabetic retinopathy; OCU100 for retinitis '
                        'pigmentosa; and OCU300, which is in Phase III '
                        'clinical trial for the treatment of ocular graft '
                        'versus host diseases. The company has a strategic '
                        'partnership with CanSino Biologics Inc. for gene '
                        'therapy co-development and manufacturing. Ocugen, '
                        'Inc. is based in Malvern, Pennsylvania.',
 'longName': 'Ocugen, Inc.',
 'market': 'us_market',
 'marketCap': 50884140,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_303874231',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -17873844,
 'nextFiscalYearEnd': 1640908800,
 'open': 0.28,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '484-328-4701',
 'previousClose': 0.2837,
 'priceHint': 4,
 'priceToBook': None,
 'priceToSalesTrailing12Months': None,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 0.4083,
 'regularMarketDayLow': 0.28,
 'regularMarketOpen': 0.28,
 'regularMarketPreviousClose': 0.2837,
 'regularMarketPrice': 0.28,
 'regularMarketVolume': 103793896,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 135007008,
 'sharesPercentSharesOut': 0.0029,
 'sharesShort': 325123,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 311151,
 'shortName': 'Ocugen, Inc.',
 'shortPercentOfFloat': 0.0031,
 'shortRatio': 0.02,
 'startDate': None,
 'state': 'PA',
 'strikePrice': None,
 'symbol': 'OCGN',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': None,
 'twoHundredDayAverage': 0.37528777,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': '169c2c50-f570-39a4-b709-68c305b79bbd',
 'volume': 103793896,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://ocugen.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '19355'}